A multistakeholder call for belzutifan biomarker data in advanced pheochromocytoma and paraganglioma.

Rodrigo A Toledo; Carlota Arenillas; Patricia L M Dahia; supporting authors

doi:10.1016/j.tem.2026.06.007

PubMed · 42481355

A multistakeholder call for belzutifan biomarker data in advanced pheochromocytoma and paraganglioma.

Rodrigo A Toledo·Carlota Arenillas·Patricia L M Dahia·supporting authors

View original source ↗Export metadata ↓

Abstract

The HIF-2α inhibitor belzutifan was recently U.S. Food and Drug Administration (FDA)-approved for advanced pheochromocytoma/paraganglioma. This multistakeholder article calls for clinical-trial genomic correlates and outcome data to clarify efficacy across these molecularly heterogeneous neuroendocrine tumors.

Explore related subjects

Pheochromocytoma Paraganglioma Humans Adrenal Gland Neoplasms Basic Helix-Loop-Helix Proteins Endothelial PAS Domain-Containing Protein 1 Biomarkers, Tumor Indenes HIF-2αbelzutifan biomarker paraganglioma pheochromocytoma Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Rodrigo A Toledo, Carlota Arenillas, Patricia L M Dahia, supporting authors. 2026-07-21. A multistakeholder call for belzutifan biomarker data in advanced pheochromocytoma and paraganglioma.. https://doi.org/10.1016/j.tem.2026.06.007

Cite the original work for its findings. Save a collection to share your selection of sources.